AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1

E-ISSN： 1873-5576|14|8|700-712

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.14, Iss.8, 2014-10, pp. : 700-712

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pentostatin in chronic lymphocytic leukemia

By Sauter Craig Lamanna Nicole Weiss Mark A

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 9, 2008-09 ,pp. : 1217-1222

Informa Healthcare

Access to resources Recommend Favorite

Targeting cAMP in chronic lymphocytic leukemia: a pathway-dependent approach for the treatment of leukemia and lymphoma

By Murray Fiona Insel Paul A

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 8, 2013-08 ,pp. : 937-949

Informa Healthcare

Access to resources Recommend Favorite

Bendamustine for treatment of chronic lymphocytic leukemia

By Chang Julie Elizabeth Kahl Brad Steven

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1495-1505

Informa Healthcare

Access to resources Recommend Favorite

Lenalidomide in lymphomas and chronic lymphocytic leukemia

By Wiernik Peter H

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 4, 2013-03 ,pp. : 475-488

Informa Healthcare

Access to resources Recommend Favorite

Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 951-957

Bentham Science Publishers

Access to resources Recommend Favorite